Shares in GC Green Cross Wellbeing surged 8.48% to 14,840 won by 10 a.m. on May 7 at the Korea Exchange, driven by a new supply contract with Japanese partner Nifuji for its GCELLE REBORNNE skin booster. This deal marks a key step in the company's push into Asia's premium aesthetics market, where demand for advanced tissue-derived treatments grows steadily. The agreement promises stable distribution and joint marketing efforts in Japan, a market prized for its regulatory rigor and consumer sophistication.
Product Innovation from Human Tissue Technology
GCELLE REBORNNE relies on human acellular dermal matrix (hADM), a biomaterial processed from donated human skin to remove cells while preserving the extracellular matrix. This structure supports skin regeneration with high biocompatibility, as the gentle processing method reduces damage to native proteins and collagen fibers. Skin boosters like this inject the matrix to stimulate fibroblasts, improve hydration, and enhance elasticity—effects rooted in the material's natural mimicry of human dermis.
Strategic Partnership Builds Japanese Foothold
Supply began in March, aligning with a domestic launch in South Korea and initial Japanese entry. GC Green Cross Wellbeing now plans a May symposium for Japanese physicians to build clinical familiarity and academic support. Nifuji's network provides immediate access to dermatology clinics, where hADM products compete with hyaluronic acid fillers and polynucleotide boosters. Japan serves as a stable base due to its mature medical device regulations and aging population seeking non-surgical rejuvenation.
Global Ambitions Echo Proven Success
The company draws on experience with Laennec, a placenta-derived therapy it established across Asian markets through local partnerships. Officials highlight this track record to fuel hADM expansion, targeting broader Asian and international growth. Such moves reflect rising global interest in regenerative aesthetics, where tissue-engineered products offer advantages in safety and efficacy over synthetic alternatives, though they face scrutiny over sourcing and processing standards.
